SC
IMNM icon

SummitTX Capital’s Immunome IMNM Stock Holding History

SummitTX Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Sell
59,476
-33,404
-36% -$715K 0.03% 416
2026
Q1 		$2.03M Sell
92,880
-34,733
-27% -$773K 0.06% 302
2025
Q4 		$2.74M Buy
+127,613
New +$2.24M 0.08% 254
2025
Q3 		– Sell
-10,695
Closed -$99.5K – 862
2025
Q2 		$99.5K Sell
10,695
-10,181
-49% -$83.5K ﹤0.01% 716
2025
Q1 		$140K Buy
+20,876
New +$200K 0.01% 748

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

SummitTX Capital's IMNM Position: Q2 2026 in Review

SummitTX Capital reduced its Immunome (IMNM) stake by 36% in Q2 2026, selling an estimated $715K and leaving 59,476 shares worth $1.26M. The position accounts for 0.03% of the portfolio, ranked #416.

SummitTX Capital first reported a position in IMNM in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.74M in Q4 2025. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • SummitTX Capital held 59,476 shares of Immunome worth $1.26M as of Q2 2026.
  • SummitTX Capital sold 33,404 Immunome shares in Q2 2026, an estimated $715K.
  • Immunome made up 0.03% of SummitTX Capital's portfolio in Q2 2026, its #416 holding.
  • SummitTX Capital first reported a position in Immunome in Q1 2025 and has held it in 5 quarters since.
  • SummitTX Capital's Immunome position peaked at $2.74M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.